Oral Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors: Call to Action
JCO Oncology Practice · 2025-08 · 21 (8) · 1073-1078
DOI: 10.1200/op-24-00812 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2025-08. Verfasst von Alessandro Villa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Oral Medicine, Oral Oncology and Dentistry. Miami Cancer Institute, Baptist Health South Florida, Miami, FL. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Oral Medicine, Oral Oncology and Dentistry. Miami Cancer Institute, Baptist Health South Florida, Miami, FL.
- Department of Orofacial Sciences, School of Dentistry, University of California San Francisco, San Francisco, CA.
- University of Michigan Health System, Ann Arbor, MI.
- American Society of Clinical Oncology, Alexandria, VA.
- School of Dental Medicine, UConn Health, Farmington, CT.
ORCID-Profile: Alessandro Villa, Christina Lacchetti, Douglas E Peterson
Zitieren
APA
Villa, A., Schneider, B. J., Lacchetti, C., Oliver, T. K., & Peterson, D. E. (2025). Oral Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors: Call to Action. JCO Oncology Practice, 21(8), 1073-1078. https://doi.org/10.1200/op-24-00812
Vancouver
Villa A, Schneider BJ, Lacchetti C, Oliver TK, Peterson DE. Oral Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors: Call to Action. JCO Oncology Practice. 2025;21(8):1073-1078. doi:10.1200/op-24-00812
BibTeX
@article{Villa2025,
author = {Villa, Alessandro and Schneider, Bryan J and Lacchetti, Christina and Oliver, Thomas K and Peterson, Douglas E},
title = {Oral Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors: Call to Action},
journal = {JCO Oncology Practice},
year = {2025},
volume = {21},
number = {8},
pages = {1073--1078},
doi = {10.1200/op-24-00812}
}
EUVIMED